There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Document (FAD) on tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...

The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Tebentafusp (Kimmtrak, Immunocore) is indicated 'as monotherapy for the treatment of human leukocyte antigen (HLA)‑A*02:01-positive adult patients with unresectable or metastatic uveal melanoma'. The ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. The minutes of each evaluation committee meeting, which include the names of ...

Interstitial cystitis, also known as bladder pain syndrome, is a chronic inflammatory condition of the bladder. The main symptoms are pelvic pain, urinary urgency, urinary frequency and nocturia.

NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 5 sources on ...